#JPM22 - Dealmaking in 2022: What's Big Pharma looking for and what is it willing to pay?
Okay, well, thanks everybody for coming out today. We had a ton of registrations for this panel discussion about dealmaking in 2022. I think that every year is a big year when it comes to dealmaking, M&A, and business development deals. And we’re certainly seeing a lot of interest this year, particularly after a very interesting 2021 — set the stage for a lot of people looking at where they’re at in terms of strategy, and how they position their company going into the new year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters